Sangamo Therapeutics Appoints Karen Smith to its Board of Directors

RICHMOND, Calif., June 28, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the appointment of Dr. Karen Smith, an accomplished drug development executive, to the Company's Board of Directors.

"Karen's extensive experience in drug development, registration and commercialization will benefit Sangamo tremendously, and I'm pleased to welcome her to our board," said Dr. Sandy Macrae, Chief Executive Officer of Sangamo. "Beyond her specific industry expertise, she is a strong and accomplished leader who will help Sangamo become a fully integrated biotechnology company delivering important new genomic therapies to patients."

Dr. Smith has over 20 years of biopharmaceutical industry experience in the United States, Europe, Canada and Asia. She has overseen more than 50 clinical trials and more than 20 regulatory approvals leading to global product launches of small molecules, biologics and devices. Most recently, she served as Executive Vice President, Global Head R&D, and Chief Medical Officer of Jazz Pharmaceuticals, Inc. Prior to joining Jazz in 2015, Dr. Smith served as Senior Vice President, Global Medical Affairs and Global Dermatology Head for Allergan plc. From 2008 to 2011, she held leadership positions in External Medical Relations and Global Development at AstraZeneca, and from 2002 to 2008 she held various senior management and clinical roles with Bristol-Myers Squibb, including Head of U.S. Clinical Operations. Dr. Smith currently is a member of the Board of Directors of Acceleron Pharma and a Board Advisor for the Australian Philanthropic 'Eliminate Cancer' Initiative. She received a B.App.Sc. in Biotechnology and a B.Sc. in Haematology from Curtin University of Technology, an M.D. from the University of Warwick, her Ph.D. in Oncology Molecular Genetics from the University of Western Australia, an M.B.A. from the University of New England in Australia, and a Master of Laws (L.L.M.) in Health Law from the University of Salford.

About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has open Phase 1/2 clinical trials in hemophilia A and hemophilia B, lysosomal storage disorders MPS I and MPS II, as well as beta thalassemia. Sangamo has an exclusive, global collaboration and license agreement with Kite, a Gilead company, for engineered cell therapies for oncology, with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington's disease. For more information about Sangamo, visit the Company's website at www.sangamo.com.

Forward-Looking Statements
This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, the Company's intent to become a fully integrated biotechnology company delivering important new genomic therapies to patients. Actual results may differ materially from these forward-looking statements due to a number of factors, including risks related to the ability of the Company to successfully develop and commercialize any of its product candidates. Additional risks and uncertainties relating to Sangamo and its business can be found under the heading "Risk Factors" in Sangamo's most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2018. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo Therapeutics, Inc.

Related Links

http://www.sangamo.com